Shaanxi Kanghui Pharmaceutical Co., Ltd.
603139.SS · SHH
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 491.51M | 188.49M | -75.69M | -63.06M | -0.63 |
| 2023 FY | 672.96M | 183.75M | -61.80M | -26.16M | -0.26 |
| 2024 FY | 561.63M | 155.73M | -122.99M | -89.63M | -0.90 |
| 2025 FY | 471.29M | 119.48M | -343.46M | -333.45M | -3.34 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 1.82B | 795.75M | 226.27M | 531.70M | 973.73M |
| 2023 FY | 2.05B | 1.03B | 163.75M | 484.44M | 949.23M |
| 2024 FY | 1.89B | 980.94M | 97.60M | 521.12M | 857.32M |
| 2025 FY | 1.81B | 1.25B | 107.71M | 706.20M | 524.92M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 50.43M | -138.13M | -87.70M | -7.39M | 14.63M |
| 2023 FY | -72.13M | -72.38M | -144.52M | -30.73M | -63.45M |
| 2024 FY | 37.29M | -46.66M | -9.37M | -28.93M | -45.22M |
| 2025 FY | -16.72M | -15.53M | -32.25M | -27.86M | -9.78M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 1.78B | 2.08B | — | — | — |
| 2023 FY | 1.89B | 2.21B | — | — | — |
| 2024 FY | 1.43B | 1.85B | — | — | — |
| 2025 FY | 2.04B | 2.64B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 126.18M | 36.28M | -29.66M | -22.96M | -0.23 |
| 2025 Q3 | 108.61M | 28.22M | -96.95M | -92.30M | -0.94 |
| 2025 Q4 | 115.15M | 25.30M | -189.56M | -200.95M | -2.02 |
| 2026 Q1 | 93.36M | 31.68M | 23.75M | 20.88M | 0.21 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 1.87B | 1.02B | 113.28M | 501.18M | 817.16M |
| 2025 Q3 | 1.89B | 1.14B | 78.49M | 667.98M | 724.84M |
| 2025 Q4 | 1.81B | 1.25B | 107.71M | 490.93M | 524.92M |
| 2026 Q1 | 1.71B | 1.12B | 52.70M | 370.82M | 545.80M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -501.50K | -1.04M | -1.54M | -7.48M | 8.36M |
| 2025 Q3 | 7.14M | -24.57M | -17.43M | — | -34.79M |
| 2025 Q4 | -7.48M | 16.16M | 8.68M | -7.14M | 9.33M |
| 2026 Q1 | 32.54M | -29.26M | 3.28M | -5.11M | -41.82M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 2.11B | 2.50B | — | — | — |
| 2025 Q3 | 2.16B | 2.75B | — | — | — |
| 2025 Q4 | 2.04B | 2.42B | — | — | — |
| 2026 Q1 | 2.63B | 2.95B | — | — | — |